Kulkarni, Harshad R.

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 3,308

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 141

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: Prognostic parameters and overall survival

Chantadisai, M., Kulkarni, H. R., & Baum, R. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Acute Myeloid Leukemia ResearchRadiopharmaceutical Chemistry and Applications

Cited by 43

225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.

Zhang, J., Kulkarni, H. R., & Baum, R. P. (2021) · Clinical Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 19